MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1α expression in third-sphere forming breast cancer stem cell-like cells

Cancer Science

Volumn 103, Issue 6, 2012, Pages 1058-1064

  Han, Mingli ^a,b   Wang, Yimeng ^a   Liu, Manran ^b   Bi, Xiaokai ^a   Bao, Junjie ^c   Zeng, Ni ^a   Zhu, Zhikun ^a   Mo, Zhiqiang ^a   Wu, Chengyi ^a   Chen, Xin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c Dazhou Central Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTAGOMIR; CELL MARKER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 21; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VIMENTIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STEM CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRUCTURE; CONTROLLED STUDY; CYTOLOGY; DRUG ANTAGONISM; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

ACTINS; ANTIGENS, CD24; ANTIGENS, CD44; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOENZYMES; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDES; RETINAL DEHYDROGENASE; SPHEROIDS, CELLULAR; VIMENTIN;

EID: 84861686487     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02281.x     Document Type: Article

References (39)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8.
2. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67.
3. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007; 1: 241-2.
4. Sottoriva A, Verhoeff JJ, Borovski T et al. Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. Cancer Res 2010; 70: 46-56.
5. Charafe-Jauffret E, Ginestier C, Iovino F et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16: 45-55.
6. Dontu G, Abdallah WM, Foley JM et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-70.
7. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell progerties. Cancer Res 2005; 65: 5506-11.
8. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
9. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-42.
10. Lee JM, Dedhar S, Kalluri R et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-81.
11. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119: 1429-37.
12. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
13. Morel AP, Lievre M, Thomas C et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008; 3: e2888.
14. Santisteban M, Reiman JM, Asiedu MK et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009; 69: 2887-95.
15. Aktas B, Tewes M, Fehm T et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009; 11: R46.
16. Shipitsin M, Campbell LL, Argani P et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11: 259-73.
17. Sarrio D, Rodriguez-Pinilla SM, Hardisson D et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008; 68: 989-97.
18. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009; 69: 4116-24.
19. Heddleston JM, Li Z, McLendon RE et al. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8: 3274-84.
20. Bar EE, Lin A, Mahairaki V et al. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 2010; 177: 1491-502.
21. Hill RP, Marie-Egyptienne DT, Hedley DW. Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 2009; 19: 106-11.
22. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
23. Soeda A, Park M, Lee D et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28: 3949-59.
24. Gustafsson MV, Zheng X, Pereira T et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9: 617-28.
25. Jögi A, Øra I, Nilsson H et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 2002; 99: 7021-6.
26. Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
27. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
28. Si ML, Zhu S, Wu H et al. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-803.
29. Yan LX, Wu QN, Zhang Y et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 2011; 13: R2.
30. Huang TH, Wu F, Loeb GB et al. Upregulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem 2009; 284: 18515-24.
31. Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008; 14: 2348-60.
32. Bao B, Wang Z, Ali S et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011; 307: 26-36.
33. Braun J, Hoang-Vu C, Dralle H et al. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene 2010; 29: 4237-44.
34. Liu M, Casimiro MC, Wang C et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA 2009; 106: 19035-19.
35. Liu M, Ju X, Willmarth NE et al. Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. Am J Pathol 2009; 174: 1910-20.
36. Sapra P, Kraft P, Pastorino F et al. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis 2011; 14: 245-53.
37. Morimoto K, Kim SJ, Tanei T et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009; 100: 1062-8.
38. Neumeister V, Agarwal S, Bordeaux J et al. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol 2010; 176: 2131-8.
39. Kai M, Onishi H, Souzaki M et al. Semi-quantitative evaluation of CD44(+)/CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method. Cancer Sci 2011; 102: 2132-8.